Unión Europea -
español -
EMA (European Medicines Agency)
blenrep
glaxosmithkline (ireland) limited - belantamab mafodotin - mieloma múltiple - agentes antineoplásicos - blenrep is indicated as monotherapy for the treatment of multiple myeloma in adult patients, who have received at least four prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-cd38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.
Unión Europea -
español -
EMA (European Medicines Agency)
lumoxiti
astrazeneca ab - moxetumomab pasudotox - leucemia, hairy cell - agentes antineoplásicos - lumoxiti as monotherapy is indicated for the treatment of adult patients with relapsed or refractory hairy cell leukaemia (hcl) after receiving at least two prior systemic therapies, including treatment with a purine nucleoside analogue (pna).
Unión Europea -
español -
EMA (European Medicines Agency)
inrebic
bristol myers squibb pharma eeig - fedratinib dihydrochloride monohydrate - myeloproliferative disorders; primary myelofibrosis - agentes antineoplásicos - inrebic is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis who are janus associated kinase (jak) inhibitor naïve or have been treated with ruxolitinib.
Unión Europea -
español -
EMA (European Medicines Agency)
qinlock
deciphera pharmaceuticals (netherlands) b.v. - ripretinib - tumores del estroma gastrointestinal - agentes antineoplásicos - qinlock is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumour (gist) who have received prior treatment with three or more kinase inhibitors, including imatinib.
Unión Europea -
español -
EMA (European Medicines Agency)
ganirelix gedeon richter
chemical works of gedeon richter plc. (gedeon richter plc.) - ganirelix acetate - reproductive techniques, assisted; ovulation induction; infertility, female - hormonas hipofisarias e hipotalámicas y análogos - prevention of premature luteinising hormone (lh) surges in women undergoing controlled ovarian hyperstimulation (coh) for assisted reproduction techniques (art).
Unión Europea -
español -
EMA (European Medicines Agency)
tabrecta
novartis europharm limited - capmatinib dihydrochloride monohydrate - carcinoma, pulmón no microcítico - agentes antineoplásicos - tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum based chemotherapy.
Unión Europea -
español -
EMA (European Medicines Agency)
pepaxti
oncopeptides ab - melphalan flufenamide hydrochloride - mieloma múltiple - agentes antineoplásicos - pepaxti is indicated, in combination with dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-cd38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. for patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation (see section 4.
Unión Europea -
español -
EMA (European Medicines Agency)
talvey
janssen-cilag international n.v. - talquetamab - mieloma múltiple - agentes antineoplásicos - talvey is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti cd38 antibody and have demonstrated disease progression on the last therapy.
Unión Europea -
español -
EMA (European Medicines Agency)
vanflyta
daiichi sankyo europe gmbh - quizartinib dihydrochloride - leucemia, mieloide - antineoplastic agents, protein kinase inhibitors - vanflyta is indicated in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, followed by vanflyta single-agent maintenance therapy for adult patients with newly diagnosed acute myeloid leukaemia (aml) that is flt3-itd positive.
